TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development.
Add to these features the high scientific standards, informal atmosphere, and active participation by the world’s leading phase 1 investigators, and you will understand why the TAT Congress has become the prime international anticancer drug development meeting.
Fast Facts: TAT 2018 – Targeted Anticancer Therapies Congress
- Expecting over 500 participants
- No parallel sessions
- Possibility to host a satellite symposium
- More than 50 internationally renowned faculty
- Excellent networking opportunities
Past attendance
ESMO gratefully acknowledges the valuable contribution of the following organisations in the TAT Congresses over the years.
Past attendees | ||
AbbVie |
INC |
Pierre Fabre |
Amgen |
Incyte Corporation |
Roche |
Astex |
Janssen |
Sanofi |
AstraZeneca |
Lilly |
Servier |
BMS |
Merck |
SIRIC-SOCRATE |
Boehringer Ingelheim |
Novartis |
Takeda |
Celgene |
Orion Pharma |
Tesaro |
ESMO |
Pfizer |
- |
Immodulon Therapeutics |
PharmaMar |
- |
How can I participate in TAT 2018 – Targeted Anticancer Therapies Congress?
At ESMO we are committed to providing our industry partners with a variety of solutions to facilitate their presence at our congress.
Contact the ESMO Strategic Partnerships Team for more details. We look forward to hearing from you!
Who has already signed up?
ESMO gratefully acknowledges the valuable contribution the following organisations have made to the Targeted Anticancer Therapies Congress 2018. (As of January 2018):
Educational Grants
Supported by a grant from Pfizer Inc.
Gold Sponsor
Silver Sponsor
Bronze Sponsor
Supporter
